Candel Therapeutics Inc (CADL)
Healthcare
Biotechnology
10.00 $
+1.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Candel Therapeutics Inc (CADL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -38 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -5.2 | -9.1 | -22 | -31 | -34 | -27 | -38 | |
| 0.0 | 0.1 | 0.2 | 0.8 | 1.3 | 1.0 | 0.8 | |
| 0.4 | 2.1 | 3.0 | 2.3 | 3.1 | 5.3 | 3.8 | |
| 2.5 | 6.7 | 14 | -14 | – | – | – | |
| 0.5 | 1.8 | -0.9 | 0.1 | -0.4 | 0.3 | 2.2 | |
| 0.2 | 1.5 | 1.8 | 1.3 | 0.5 | 0.0 | 0.6 | |
| -36 | 38 | -1.8 | -1.3 | -0.3 | 0.0 | -0.6 | |
| – | – | 72 | – | -0.1 | – | – | |
| -0.5 | 0.5 | 20 | 20 | 0.0 | -9.2 | 36 | |
| 22 | 0.5 | 72 | 20 | -0.1 | 94 | 56 | |
| -19 | 30 | 48 | -13 | -35 | 67 | 17 | |
| -5.3 | -11 | -24 | -33 | -35 | -27 | -39 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.